Abstract
The emergence of the global Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic underscores the importance of the rapid development of a non-invasive vaccine that can be easily administered. A vaccine administered by nasal delivery is endowed with such characteristics against respiratory viruses. In this study, we generated a recombinant SARS-CoV-2 receptor-binding domain (RBD)-based subunit vaccine. Mice were immunized via intranasal inoculation, microneedle-intradermal injection, or intramuscular injection, after which the RBD-specific immune responses were compared. Results showed that when administrated intranasally, the vaccine elicited a robust systemic humoral immunity with high titers of IgG antibodies and neutralizing antibodies as well as a significant mucosal immunity. Besides, antigen-specific T cell responses were also analyzed. These results indicated that the non-invasive intranasal administration should be explored for the future SARS-CoV-2 vaccine design.
Keywords: Intranasal administration; Mucosal immunity; Neutralizing antibody; SARS-CoV-2.
【저자키워드】 neutralizing antibody, SARS-CoV-2, intranasal administration, mucosal immunity, 【초록키워드】 SARS-CoV-2, Vaccine, immune response, pandemic, Immunity, antibody, nasal, SARS-CoV-2 vaccine, respiratory viruses, Humoral immunity, Characteristics, respiratory, T cell response, intranasal, mucosal, administration, Intramuscular injection, Non-invasive, subunit, domain, injection, Administered, immunized, robust, Result, analyzed, intranasally, indicated, the vaccine, elicited, titers of IgG, 【제목키워드】 SARS-CoV-2, Vaccine, protective immunity, RBD, administration,